Order Article Reprints

Agrawal A, Srivastava MVP, Bhatia R, Goyal V, Singh MB, Vishnu VY, Prabhakar A. A Real-World Experience of Azathioprine Versus First-Line Disease-Modifying Therapy in Relapsing-Remitting Multiple Sclerosis—A Prospective Cohort Study. Brain Sciences. 2023; 13(9):1249. https://doi.org/10.3390/brainsci13091249

Agrawal, Arpit, M. V. Padma Srivastava, Rohit Bhatia, Vinay Goyal, Mamta Bhushan Singh, Venugopalan Y. Vishnu, and Anuj Prabhakar. 2023. "A Real-World Experience of Azathioprine Versus First-Line Disease-Modifying Therapy in Relapsing-Remitting Multiple Sclerosis—A Prospective Cohort Study" Brain Sciences 13, no. 9: 1249. https://doi.org/10.3390/brainsci13091249

Agrawal, A., Srivastava, M. V. P., Bhatia, R., Goyal, V., Singh, M. B., Vishnu, V. Y., & Prabhakar, A. (2023). A Real-World Experience of Azathioprine Versus First-Line Disease-Modifying Therapy in Relapsing-Remitting Multiple Sclerosis—A Prospective Cohort Study. Brain Sciences, 13(9), 1249. https://doi.org/10.3390/brainsci13091249